Bill Baruch Buys Edwards Lifesciences: A Healthcare Investment Analysis

Investment Rationale for Edwards Lifesciences

• 💡 Bill Baruch discusses his recent purchase of Edwards Lifesciences, a heart valve company, noting that the healthcare sector has underperformed recently.
• 🎯 The investment is positioned as a play on a potential "sleeping giant" awakening, given the stock's multi-year compounder history and recent dormancy.
• 📈 Edwards Lifesciences was a significant performer from 2013 to 2021, and Baruch believes its multiple has compressed, presenting an opportunity.

Growth Prospects and Innovation

• 🚀 Baruch anticipates that Edwards Lifesciences will begin to see the integration of artificial intelligence and other innovations coming to fruition.
• 💰 A key driver for the investment is the expectation of increasing free cash flow, despite past market concerns over acquisitions.
• ⚠️ While there is resistance around $95, surpassing this level could signal a significant upward trend and renewed compounding.

Addressing Market Concerns (Tariffs and Guidance)

• 🏥 The company, primarily known for heart valves, recently maintained its guidance despite a projected 5-10 cent negative impact on EPS due to a potential 10% tariff.
• 💰 Baruch is not overly concerned about the tariff, believing that increased free cash flow will offset potential negativity.
• 📊 He suggests that the healthcare space, being on the back burner from a flow standpoint, is poised to see increased investment, which could further benefit companies like Edwards Lifesciences.